Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy.

J Hematol Oncol · 2009 · PMC2686726 · PMID 19386128

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the three studies designed to compare outcomes from standard treatment with or without cetuximab [ 22 , 24 , 25 ], patients with KRAS MT tumors showed a decrease in TTP in the cetuximab-containing arm compared with the standard treatment arm, although the difference in each individual study did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.